CoDon

CoDon FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of CoDon (CNW.F) as of Oct 30, 2026 is 90.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 71.92 % — a change of 26.06% (higher).

FCF Conversion

90.66 %

YoY

26.06%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of CoDon is 2021 90.66 % . FCF Conversion Rate (FCF/EBITDA) of CoDon was 2020 71.92 % . It decreases by 26.06% higher compared to the previous year.

The CoDon FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
76.27 EUR
Jan 1, 2015
149.40 EUR
Jan 1, 2016
103.73 EUR
Jan 1, 2017
139.49 EUR
Jan 1, 2018
248.56 EUR
Jan 1, 2019
106.04 EUR
Jan 1, 2020
71.92 EUR
Jan 1, 2021
90.66 EUR
The CoDon FCF Conversion history
YEARFCF ConversionYoY
90.66 %+26.06%
71.92 %-32.18%
106.04 %-57.34%
248.56 %+78.19%
139.49 %+34.48%
103.73 %-30.57%
149.40 %+95.88%
76.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CoDon Stock analysis

What does CoDon do? co.don AG develops and sells cell-based biological drugs for regenerative medicine, focusing on orthopedic and neurosurgical applications. Its key products include co don chondrotransplant for knee cartilage defects, co don chondrosphere for three-dimensional cartilage cultivation, co don chondrotransplant DISC for intervertebral disc regeneration, and co don osteotransplant DENT for dental bone cell transplants. The company targets medical professionals and clinics in Germany and other European countries, with its products treating conditions like focal cartilage defects, lumbar disc herniation, non-union fractures, and dental disorders. co.don AG generates revenue through direct sales of these specialized biological drugs to healthcare providers. The firm operates with a product portfolio centered on autologous cell therapies, where patient-derived cells are cultivated for personalized treatments. co don chondrotransplant DISC addresses spinal disc issues, while co don osteotransplant DENT serves dental applications, expanding the company's reach beyond orthopedics. All products are manufactured in-house and sold directly to medical institutions across Europe, with no mention of third-party distribution or additional revenue streams in the business description. co.don AG's revenue model relies on the commercialization of its four primary product lines, each addressing specific medical conditions. The company's focus on regenerative treatments for cartilage, disc, and dental applications ensures a steady demand from clinics specializing in these areas. Sales are conducted within Germany and other European markets, with no indication of global expansion or additional segments beyond the described product uses. CoDon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CoDon stock

FCF Conversion Rate (FCF/EBITDA) of CoDon is 90.66 % in 2021.

FCF Conversion Rate (FCF/EBITDA) of CoDon changed from 71.92 % to 90.66 %, representing a 26.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) CoDon since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s CoDon with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CoDon

All Key Metrics — CoDon